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background: There are limited data regarding frequency of use and outcomes of the only approved drug coated stent (DCS; Zilver PTX®; 
Cook) during endovascular revascularization of infrainguinal arteries.
methods: We compared DCS to bare metal stent (BMS) use in procedures performed from January 2013 - August 2014, included in the 
multicenter Excellence in Peripheral Artery Disease (XLPAD) registry (n=238).
results: DCS was implanted during 52 (21.8%) procedures in 47 (23.1%) patients. There was no difference in age (63.9±9.2 vs. 64.3±8.6; 
p=0.786), gender (25.0% vs. 19.3% female; p=0.438), and ankle brachial index (0.74±0.22 vs. 0.75±0.30; p=0.986) of patients receiving 
DCS or BMS. However, DCS was less frequently used in patients with diabetes (33.3% vs. 53.8%; p=0.008) and critical limb ischemia 
(12.5% vs. 30.1%; p=0.010). Lesion location, length, and treatment of chronic total occlusions were similar across both groups. However, 
DCS were more frequently used for the treatment of in-stent restenosis (ISR) (28.8% vs. 19.3%; p=0.180). Dual antiplatelet therapy was 
prescribed to 86.5% of DCS recipients compared with 91.9% of BMS (p=0.277). Peri-procedural complications were not different (5.8% vs. 
5.4%; p=1.000), and overall clinical outcomes, except for stent thrombosis, were similar across both groups (Figure 1).
Conclusion:  DCS use for infrainguinal peripheral artery revascularization is predominantly used for the treatment of ISR and is associated 
with higher rates of stent thrombosis.
 
